179 related articles for article (PubMed ID: 16641914)
1. Malignant melanoma and bone resorption.
Lau YS; Sabokbar A; Giele H; Cerundolo V; Hofstetter W; Athanasou NA
Br J Cancer; 2006 May; 94(10):1496-503. PubMed ID: 16641914
[TBL] [Abstract][Full Text] [Related]
2. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
Sabokbar A; Kudo O; Athanasou NA
J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.
Lau YS; Adamopoulos IE; Sabokbar A; Giele H; Gibbons CL; Athanasou NA
Br J Cancer; 2007 Jun; 96(11):1716-22. PubMed ID: 17533390
[TBL] [Abstract][Full Text] [Related]
4. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA
J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469
[TBL] [Abstract][Full Text] [Related]
5. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.
Haynes DR; Crotti TN; Potter AE; Loric M; Atkins GJ; Howie DW; Findlay DM
J Bone Joint Surg Br; 2001 Aug; 83(6):902-11. PubMed ID: 11521937
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
[TBL] [Abstract][Full Text] [Related]
7. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
Itonaga I; Sabokbar A; Murray DW; Athanasou NA
Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
9. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
13. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM
Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
18. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
[TBL] [Abstract][Full Text] [Related]
20. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
